A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical Carcinoma

Summary

The purpose of this study is to evaluate the efficacy and safety of nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy versus placebo combined with concurrent chemoradiotherapy in patients with locally advanced cervical squamous cell carcinoma. The primary hypotheses are that nimotuzumab plus concurrent chemoradiotherapy sequential maintenance therapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival.

Timeline

Start

2024-04-01

Primary completion

2030-04-01

Completion

2030-04-01

Publications

• Wei S, Li X, Liu Z, Wei L, Zou L, Zhang Y, Sun X, Gao Y, Zhuo Y, Zhang M, Qu A, Zhang H, Guo H, Jiang P, Wang J. Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial. J Gynecol Oncol. 2026 May;37(3):e46. doi: 10.3802/jgo.2026.37.e46. Epub 2025 Dec 11.

Drugs

Indications